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Abstract 
Purpose: To investigate the effect of moxifloxacin on paraoxonase-1 (PON1) activity, and serum 
oxidative stress in patients with multiple drug-resistant tuberculosis (MDR-TB).  
Methods: A total ofof 130 MDR-TB patients who were treated with moxifloxacin from October 2014 to 
October 2010 in Eastern Medical District of Linyi People's Hospital of Shandong Province, China were 
randomly divided into an observation group (65 cases, moxifloxacin group) and control group (65 cases, 
non-moxifloxacin group). Total oxidant status (TOS), total antioxidant status (TAS), oxidative stress 
index (OSI), PON1 levels and treatment efficacy for groups were determined.  
Results: Compared with pre-treatment levels, TOS (23.3 ± 4.7 vs 13.9 ± 3.3 umol H2O2 Eq/L, t = 13.20, 
p = 0.00) and OSI (17.4 ± 4.8 vs 5.7 ± 1.4 U, t = 18.87, p = 0.00) of the observation group significantly 
decreased, while TAS (1.4 ± 0.5 vs 3.5 ± 0.7 umol Trolox Eq/L, t = 19.68, p = 0.00) and PON1 (15.5 ± 
6.9 vs 31.1 ± 8.3 U/L, t = 11.65, p = 0.00) significantly increased. TOS (23.3 ± 4.7 vs 13.9 ± 3.3 umol 
H2O2 Eq/L, t = 7.73, p < 0.05) and OSI (16.9 ± 5.5 vs 7.4 ± 3.2U, t = 12.04, p = 0.05) reduced 
significantly in the control group. Moxifloxacin correlated positively with △TAS (r = 0.697, p = 0. 04) and 
△PON1 (r = 0.785, p = 0.01), but correlation with △TOS (r = -0.625, p = 0.01) was negative. Efficacy 
was significantly higher in the observation group than that in the control group (81.54 % vs 56.92 %, p = 
0.00).  
Conclusion: Oxidative stress injury in MDR-TB patients may be effectively managed by combination of 
moxifloxacin with anti-TB treatment 
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Tuberculosis (TB) is one of the global public 
health problems. In recent years, with greater 
attention paid to TB prevention and treatment 
technology, the incidence of TB has declined. 
However, there are still a large population of 
patients with TB [1,2]. China ranks second in the 
world, with respect to the number of TB patients 
[3]. Due to irregularities in availability of 
appropriate clinical medications and variations in 
the causative organism, Mycobacterium 
tuberculosis, the incidence of drug resistance is 
gradually increasing. Multiple drug-resistant TB 
(MDR-TB) is that patients have a resistant to two 
or more anti-TB drugs, such as the conventional 
first-line anti-TB drugs rifampicin and isoniazid.  
 
Drug resistance greatly increases the treatment 
cycle and adverse reactions, resulting in a 
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significant reduction in cure rate [4]. Relevant 
epidemiological studies have shown that total 
resistance in TB has reached up to 37.62 % [5]. 
Results of assessment by World Health 
Organization showed that the incidence of MDR-
TB in TB patients was 20 %. This is a great 
challenge to clinical treatment of TB because it 
seriously affects the quality of life and prognosis 
[6]. Therefore, the search for effective treatment 
strategies for patients with MDR-TB has become 
a subject of intensive clinical research. 
 
It has been reported that TB infection and 
prognosis may have a certain relationship with 
oxidative stress, leading to disorders in the 
balance between pro-oxidants and antioxidant 
system [7,8]. Quinolones have effects on MDR-
TB, which may be relevant with oxidative stress 






A total of 130 patients with MDR-TB treated in 
Eastern Medical District of Linyi People's 
Hospital of Shandong Province, from October 
2014 to October 2016 were enrolled. The 
diagnostic criteria were in accordance with the 
Guidelines for the Diagnosis and Treatment of 
Tuberculosis (2013 version) [10] . Inclusion 
criteria were: patients aged 18 - 60 years; 
patients who were not taking quinolone 
antibiotics (including hypnathic acid, pipemidic 
acid, norfloxacin and gatifloxacin) at least 90 
days before enrollment; patients free from 
cardiovascular disease history (including 
coronary heart disease and myocardial 
infarction); absence of significant ECG 
abnormalities like QRS wide malformations and 
QT interval prolonged; and absence of 
neuropsychiatric history like bipolar disorder and 
schizophrenia.  
 
Exclusion criteria patients with autoimmune 
diseases; long-term use of immunosuppressive 
agents; bacteria or fungal infectious diseases like 
Streptococcus pneumonia and large area of 
yellow ringworm. The ethics committee of 
hospital approved the study (approval No. 
LY2014050) whih also followed the guidelines of 
Declaration of Helsinki, as amended in 1996 [11], 
and all patients were informed. All the patients of 
this study gave their informed consent, and were 
randomly divided into observation group (65 
cases) and control group (65 cases). There was 
no significant difference between the two groups 
in with regard to their profiles, including gender, 
age, course of disease, smoking history, MDR-
TB clinical classification, and basic disease and 
laboratory tests (p > 0.05, Table 1). 
 
The control group was treated with conventional 
drug regimen, amikacin, dipasic, rifapentine and 
ethambutol, abbreviated as 6ADL2E/18DL2E; 
where A, D, L2 and E refer to amikacin, dipasic, 
rifapentine and ethambutol, respectively, while 
the figures refer to 6 and 18 months. The 
observation group was treated with moxifloxacin 
(Bayer Healthcare Co., Ltd.), specifically 
6ADL2EM/18DL2EM, where M refers to 
moxifloxacin. During the treatment, regular blood 
routine examination, liver function and kidney 
function were carried out. 
 
Determination of TAS, TOS, OSI and PON-1 in 
serum 
 
The xylenol orange method was used to 
determine the total oxidant status (TOS) by using 
an automatic biochemical analyzer (HITACHI, 
Japan). In this method, ferrous ion (Fe2+) is 
oxidized to ferric ions (Fe3+), which react with 
xylenol orange. The color intensity is proportional 
to TOS level, expressed as μmol H2O2 Equiv/L.  
 
Total antioxidant status (TAS) was measured by 
the ABTS method using automatic biochemical 
analyzer (HITACHI, Japan). The total 
antioxidants reacted with ABTS (2, 2'-amino-di-3-
ethyl-benzothiazolinesulfonic acid-6 ammonium 
salt). TAS level, which was expressed as mmol 
Trolox Equiv/L is proportional to the magnitude of 
color change seen in the reaction. Oxidative 
Stress Index (OSI) was obtained as in Eq 1. 
  
OSI = {(TOS)/(TAS×1000)}100. …………… (1) 
 
For serum PON-1 activity, venous blood samples 
(4 %) was drawn after 8h fast and centrifuged at 
3000 r/min at 4 oC for 10 min to collect the 
supernatant. PONI-1 was assayed by 
spectrophotometry (SP). Activity was calculated 
as in Eq 2 [12]. 
 
PON1 activity (ku/L) = {A×F×FV/(t×SV×L×ε)}103 …. (2)  
 
where A is the net absorbance value (i.e. the 
absorbance value of the specimen minus the 
absorbance value of the serum control and the 
substrate control); F is the dilution factor of the 
specimen, FV is the final volume of the reaction, t 
is the reaction time (min), SV is the sample 
volume (L), L is the optical path (cm), and ε is the 
molar extinction coefficient. One unit of pon-1 
activity was defined as 1μ enzyme required to 
catalyze the hydrolysis of 1μmol phenylacetate 
per minute. 
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Criteria for determination of efficacy 
 
Bacteriological evaluation or X-ray examination 
was used for efficacy determination. If sputum 
examination (3 consecutive sputum smears and 
1 sputum TB) showed negative results or 
decreased amounts of inoculum, the treatment 
was effective, but if it was unchanged or if the 
amount of inoculum was increased, the treatment 
was ineffective. X-ray evaluation results were 
deemed to indicate effective treatment if the 
lesions were resolved, while deterioration of 
lesions or absence of significant changes in 




All the data in this study were analyzed by SPSS 
22.0 Statistical Software. Measurement data of 
normal distribution are expressed as mean ± SD, 
and t-test or analysis of variance (ANOVA) was 
used for group comparison. Enumeration data 
are presented as {n (%)}, and analyzed by Chi-
square test. Pearson or Spearman correlation 
analysis was employed for correlation analysis, 





General information of the two groups 
 
There were no significant differences in gender, 
age, duration of disease, smoking history and 
other general data (p > 0.05). The prevalence of 
hematogenous disseminated TB, infiltrative 
pulmonary TB, chronic fibrous TB and TB 
pleurisy were no significant differences (p > 
0.05). In addition, the proportion of patients with 
chronic bronchitis and diabetes showed no 
significant difference (p > 0.05), the estimated 
values of albumin, neutrophils, white blood cell, 
alanine aminotransferase and serum creatinine 
had no significant differences (p > 0.05, Table 1). 
 
Changes in serum TAS, TOS, OSI and PON1 
levels in both groups before and after 
treatment 
 
There were no significant differences in TOS, 
OSI and PON1 levels of two groups before 
treatment (p > 0.05). In the observation group, 
the levels of TOS and OSI were significantly 
lower than those in the control group, while TAS 
and PON1 were significantly higher than those in 
the control group (p < 0.05). The levels of TOS 
and OSI in the observation group were 
significantly decreased, while the levels of TAS 
and PON1 were significantly increased after 
treatment (p < 0.05). When compared with those 
before treatment, the levels of TOS and OSI 
lowered significantly after treatment in control 
group (p < 0.05) while changes in TAS and 





In the correlation analysis between smoking 
history/diabetes/moxifloxacin/chronic 
bronchitis/moxifloxacin and TAS/TOS/OSI/PON1 
levels {△ = (after treatment - before treatment)}, 
moxifloxacin was positively in correlation with 
△TAS (r = 0.697, p = 0.04) and △PON1 (r = 
0.785, p = 0.01), but negatively correlated with 
△TOS (r = -0.625, p = 0.01). There were no 
significant differences among the other indices (p 
> 0.05, Table 3). 
 
Table 1: Demographic and general profile {(mean ± SD), n (%)} 
 
Variable Observation group (65) Control group (65) t or χ
2 p-value 
Gender (M/F) 37/28 42/23 0.81 0.37 
Age 50.2±4.7 51.1±3.9 1.19 0.24 
Duration of disease (year) 12.2±4.8 11.9±4.4 0.37 0.71 
Smoking history 19 (29.23 %) 17 (26.15 %) 0.15 0.70 
Hematogenous disseminated TB 26 (40.00 %) 29 (44.61 %) 0.28 0.59 
Infiltrative pulmonary TB 17 (26.15 %) 14 (21.54 %) 0.38 0.54 
Chronic fibrous TB 8 (12.31 %) 11 (16.92 %) 0.56 0.46 
TB pleurisy 14 (21.54 %) 11 (16.92 %) 0.44 0.50 
Diabetes 17 (26.15 %) 20 (30.77 %) 0.34 0.56 
Chronic bronchitis 7 (10.77 %) 5 (7.69 %) 0.37 0.55 
Albumin (g/L) 29.9±3.1 30.5±2.8 1.16 0.25 
White blood cell (109/L) 7.67±1.24 7.49±1.33 0.80 0.43 
Serum creatinine (umol/L) 77.1±10.4 74.6±12.5 1.24 0.22 
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Table 2: Changes of serum TAS, TOS, OSI and PON1 levels in both groups before and after treatment (mean ± 
SD) 
 
Parameter  Observation group (65) 
Control group 
(65) t or χ
2 p-value 
TAS (umol Trolox Eq/L)      
 Before 1.4±0.5 1.6±0.3 2.77 0.28 
 After 3.5±0.7* 2.0±0.6 13.12 0.00 
TOS (umol H2O2 Eq/L)      
 Before 23.3±4.7 23.6±4.4 0.38 0.71 
 After 13.9±3.3* 17.5±4.6* 5.13 0.00 
OSI (U)      
 Before 17.4±4.8 16.9±5.5 0.55 0.58 
 After 5.7±1.4* 7.4±3.2* 3.92 0.01 
PON1 (U/L)      
 Before 15.5±6.9 16.1±4.4 0.59 0.57 
 After 31.1±8.3* 19.9±7.4 8.12 0.00 
Note: Compared to pre- treatment, *p < 0.05. 
 
Table 3: Correlation analysis results 
 
Variable 









Smoking history 0.01 0.66  -0.01 0.69  -0.02 0.55  -0.03 0.55 
Diabetes -0.04 0.33  -0.03 0.049  0.04 0.26  -0.02 0.59 
Chronic bronchitis 0.01 0.61  0.06 0.14  -0.01 0.68  -0.02 0.50 
Moxifloxacin 0.70 0.04  -0.63 0.01  0. 23 0.09  0.79 0.01 
△TAS - -  -0.12 0.11  -0.02 0.19  0.24 0.11 
△TOS -0.11 0.15  - -  -0.04 0.35  -0.19 0.07 
△OSI -0.02 0.18  -0.05 0.30  - -  0.01 0.41 
△PON1 0.25 0.19  -0.19 0.09  0.06 0.41  - - 
 
Comparison of effectiveness of treatment 
between the two groups 
 
The treatment efficacy was significantly higher in 
the observation group than that in the control 
group (p < 0.05, Table 4). 
 
Table 4: Effective rate of treatment for the two groups 
{n (%)} 
 
Group Effective Ineffective 
Observation group 
(n=65) 53 (81.54) 12 (18.46) 
Control group (n = 






Studies have shown that Mycobacterium 
tuberculosis gene mutations could occur in the 
process of growth and reproduction to form 
resistant strains due to environmental factors. 
The emergence of clinically resistant strains is 
closely linked to factors such as insufficient drug 
dosage, improper medication methods, 
inadequate course of treatment or intermittent 
medication and inappropriate order of 
medication. These factors cause resistance to 
first-line drugs (isoniazid, rifampicin and 
pyrazinamide), and second-line drugs 
(injectables, fluoroquinolones and anti-
inflammatory drugs). In MDR-TB, alveolar 
macrophages and other anti-inflammatory cells 
accumulate, engulfing MDR-TB bacteria and 
releasing a large number of reactive oxygen 
species (ROS), which result in local inflammatory 
response and damage [14,15] . 
 
Quinolones, also known as pyridine carboxylic 
acids or pyridine acids, are synthetic 4-quinolone 
antibacterial drugs. Quinolones are targeted at 
DNA, thereby blocking DNA gyrase and further 
causing irreversible damage to DNA. Compared 
with the first 3 generations of quinolone 
antibiotics, moxifloxacin as a fourth-generation 
quinolone accumulates highly in respiratory 
mucosa, lung tissue, bronchoalveolar lavage fluid 
and macrophages, effectively killing lung TB 
mycobacteria [16,17]. In this study, moxifloxacin 
treatment was used in the observation group, 
and it greatly improved the effectiveness of 
MDR-TB. During infections, trauma, and 
poisoning, large amounts of inflammatory 
substances are generated, leading to imbalance 
in antioxidant system known as oxidative stress 
[9,18]. In MDR-TB patients, excessive activation 
and aggregation of macrophages and neutrophils 
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occur, with resultant imbalance between oxidant 
and antioxidant system, which accounts for high 
oxidative stress [19]. In this study, total oxidant 
status and antioxidant status gradually recovered 
in the two groups of patients after treatment: TAS 
and PON1 levels significantly increased, while 
TOS and OSI levels decreased. The degree of 
improvement was more pronounced in patients 
with moxifloxacin combination therapy. 
 
Malnutrition is one of the most important causes 
of high oxidative stress in TB patients. Poor 
appetite and inadequate intake of vitamin C and 
other antioxidants by MDR-TB patients may also 
lead to oxidative stress injury [20]. However, in 
this study, the albumin levels in the two groups of 
patients were within normal range, and their 
difference was not statistically significant. PON1 
is a calcium-sensitive lipase with the 
physiological function of hydrolyzing lipid 
peroxides in vivo. The activity of PON1 is 
significantly reduced in oxidative stress 
conditions [21]. In this study, PON1 activity was 
significantly decreased in both groups before 
treatment, and increased after treatment, with 
more significant increase in the observation 
group. In the correlation analysis, moxifloxacin 
had a positive correlation with PON1 activity, and 
its mechanism of action might be related to 
mitigation of Mycobacterium tuberculosis-
mediated chronic oxidative stress injury [22,23] . 
     
Limitations of the study 
 
However, this study is a controlled study using a 
small sample, and the specific mechanism of 
action of moxifloacin is yet to be elucidated. 
Thus, further, well-designed studies based on 




The results of this study indicate that 
moxifloxacin can improve the imbalance in 
oxidant-antioxidant system in patients with MDR-
TB, reduce the associated high oxidative stress, 
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